$ARDX

Brady James Parker sold $58K of ARDX

Brady James Parker (Chief Human Resources Officer) sold 15,136 shares of ARDELYX, INC. (ARDX) at $3.86 across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Brady James Parker
Published Aug 25, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect ARDX's stock price or investor sentiment.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or compensation changes not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-08-25

Background

Form 4 filing discloses insider trades to the SEC; required for transparency.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Chief Human Resources Officer Brady James Parker sold 15,136 shares for $58,378, reducing his stake to 245,930 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and typical insider trading volumes.

Market effects

None; HR executive sale does not affect sector dynamics.

None; company is US‑listed with limited regional relevance.

None; isolated insider transaction.

Counterpoint

Even small insider sales can signal concerns, but no corroborating evidence here.

Key entities

  • Brady James Parker

    Chief Human Resources Officer of ARDELYX, Inc.

  • ARDELYX, Inc.

    Biopharmaceutical company listed under ticker ARDX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow